GERREN WILSON: Open Payments
NPI 1366837775 · MARRERO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,948 in 91 payments from 13 companies in 2025. Trend: 2023 $2,301 · 2024 $2,085 · 2025 $1,948
Food & beverage: $1,948
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $492 |
| Alkermes, Inc. | 12 | $352 |
| Otsuka America Pharmaceutical, Inc. | 19 | $334 |
| Janssen Pharmaceuticals, Inc | 7 | $242 |
| Supernus Pharmaceuticals, Inc. | 3 | $115 |
| Vanda Pharmaceuticals Inc. | 5 | $107 |
| Corium, LLC | 4 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Lundbeck LLC | 2 | $32 |
Products named: VRAYLAR, ARISTADA, ABILIFY ASIMTUFII, INVEGA, REXULTI, LYBALVI, Qelbree, FANAPT.
Industry payments across LA — which companies pay providers there.
